Top Tips For Providing The Right Amount Of Detail In First-In-Human Common Technical Documents

At the first-in-human stage, sponsors are working with incomplete data, evolving formulations, and limited process characterization. Yet regulatory submissions still require a structured, credible account of manufacturing processes, controls, and reference standards in the common technical document. The gap between what is known and what must be documented creates real uncertainty about how much detail is sufficient, and where gaps in data require justification rather than silence.

This white paper offers practical guidance on structuring a FIH clinical trial application dossier, with a focus on CMC expectations, the rationale sponsors should provide for process and method selection, and how to address the comparison between preclinical and clinical materials.

Explore the full guidelines to approach your next FIH submission with greater confidence.